<DOC>
	<DOC>NCT00197093</DOC>
	<brief_summary>This study is a placebo-controlled study to assess the safety and tolerability of a novel antipsychotic medication, (773812) when given to schizophrenic patients for twenty-eight days. Assessments include blood sampling to determine drug concentrations, psychiatric assessments while under treatment, and movement assessments to evaluate potential side effects.</brief_summary>
	<brief_title>In-Patient Study In Schizophrenic Patients</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Must have schizophrenia that has been stable for at least three months. Willing to discontinue current antipsychotic medications (under supervision) prior to the study. Willing to live at the study center for a total of 38 days and then return for three followup visits. Taking medications for conditions other than schizophrenia. History of alcohol or drug abuse within six months of the study, and their alcohol consumption must meet moderate guidelines.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>